HISTORY	MATURATION INDEX
SPECIMEN SOURCE: CERVICAL/VAGINAL/1 ThinPrep® Slide MENOPAUSAL: YES	ESTROGEN EFFECT (HORMONAL PATTERN): COMPATIBLE WITH AGE AND/OR HISTORY.

PAP TEST RESULTS WITH IMAGER

Date Reported: 2/19/2008

NEGATIVE for intraepithelial lesion or malignancy. Endocervical cells or associated benign metaplastic cells present.

Management Recommendation: Cytology Negative, HPV Negative: Routine Screening at clinically appropriate interval, as suggested by the Consensus Workshop or at three years. (Obstetrics and Gynecology 2004;103:302-309)

Pathologist: JOHN COMPAGNO M.D.,MEDICAL DIRECTOR

HUMAN PAPILLOMA VIRUS TEST RESULTS BY PCR

Date Reported: 2/14/2008

HPV Identification

Negative

The sample is negative for the presence of HPV DNA. These results do not exclude the possibility of HPV not detected due to sampling or assay sensitivity. This specimen tested negative for: LVX160, CP8061, CP6108, 6, 11, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 72, 73, 74, 81, 82, 83, 84 and "Unknown." The presence of certain HPV types is an established risk factor for the development of cellular dysplasia or neoplasia. Identification of the specific HPV type permits the assignment of disease risk, and is important to the clinical management of the patient.

Pathologist: JOHN COMPAGNO, M.D., MEDICAL DIRECTOR

CYSTIC FIBROSIS TEST RESULTS BY PCR

Date Reported: 2/14/2008

Cystic Fibrosis : Positive for DeltaF508 mutation

This individual is heterozygous for (has one copy of) the mutation DeltaF508.  This individual is a female. As a carrier of the DeltaF508 mutation no symptoms would be expected. When this mutation is present in a CF affected individual it may be associated with severe pulmonary dysfunction and pancreatic insufficiency. (Kerem, E.; et al., The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta-F508). New Eng. J. Med. 323: 1517-1522, 1990.)

See http://www.wcpl.com/cf.asp for methodology, further considerations as well as carrier screen information regarding Cystic Fibrosis.

Pathologist: JOHN COMPAGNO, M.D., MEDICAL DIRECTOR

Note: For FDA comments, see http://www.wcpl.com/FDA.asp

Note: The following tests are available for 60 days post collection. Please call (800) 794-9737 for additional testing, if desired.

• CHLAMYDIA/GONORRHEA (CT-NG) BY PCR
• HERPES SIMPLEX VIRUS (HSV) BY PCR
• INHERITED THROMBOPHILIA (IHT) BY PCR

712 Alfred Nobel Drive . Hercules, CA 94547 . toll free 800.794.9737 . fax 510.662.5240 . www.wcpl.com . John Compagno, M.D., Medical Director

PATHOLOGY/CYTOPATHOLOGY CONSULTATION REPORT